JAG
ABBV icon

Journey Advisory Group’s AbbVie ABBV Stock Holding History

Journey Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Buy
47,472
+181
+0.4% +$38.9K 0.91% 30
2026
Q1 		$10.3M Sell
47,291
-785
-2% -$174K 0.88% 29
2025
Q4 		$11M Sell
48,076
-2,209
-4% -$503K 0.92% 26
2025
Q3 		$11.6M Buy
50,285
+1,010
+2% +$206K 0.86% 27
2025
Q2 		$9.15M Sell
49,275
-148
-0.3% -$27.5K 0.71% 32
2025
Q1 		$10.4M Sell
49,423
-628
-1% -$122K 0.85% 28
2024
Q4 		$8.58M Hold
50,051
– – 1.03% 28
2024
Q3 		$8.58M Hold
50,051
– – 1.03% 28
2024
Q2 		$8.58M Sell
50,051
-927
-2% -$154K 1.03% 28
2024
Q1 		$9.28M Buy
50,978
+49
+0.1% +$8.45K 1.14% 24
2023
Q4 		$7.89M Sell
50,929
-2,064
-4% -$301K 1.07% 27
2023
Q3 		$7.9M Buy
52,993
+2,071
+4% +$304K 1.18% 24
2023
Q2 		$6.86M Sell
50,922
-11,387
-18% -$1.67M 1.02% 26
2023
Q1 		$9.93M Buy
62,309
+8,579
+16% +$1.31M 1.56% 17
2022
Q4 		$8.68M Buy
53,730
+6,586
+14% +$1.01M 2.16% 7
2022
Q3 		$6.33M Buy
47,144
+2,546
+6% +$365K 1.61% 12
2022
Q2 		$6.25M Buy
44,598
+19,539
+78% +$2.99M 1.44% 14
2022
Q1 		$4.06M Buy
25,059
+3,795
+18% +$551K 1.03% 22
2021
Q4 		$2.88M Buy
21,264
+2,645
+14% +$312K 0.8% 28
2021
Q3 		$2.01M Buy
18,619
+1,713
+10% +$196K 0.65% 37
2021
Q2 		$1.9M Buy
16,906
+1,445
+9% +$163K 0.6% 47
2021
Q1 		$1.67M Buy
15,461
+536
+4% +$57.3K 0.59% 50
2020
Q4 		$1.6M Buy
+14,925
New +$1.43M 0.6% 48

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Journey Advisory Group's ABBV Position: Q2 2026 in Review

Journey Advisory Group increased its AbbVie (ABBV) stake by 0.38% in Q2 2026, buying an estimated $38.9K and bringing the position to 47,472 shares worth $11.9M. The position accounts for 0.91% of the portfolio, ranked #30.

Journey Advisory Group first reported a position in ABBV in Q4 2020 and has held it in 23 quarters since. 2,771 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Journey Advisory Group held 47,472 shares of AbbVie worth $11.9M as of Q2 2026.
  • Journey Advisory Group bought 181 AbbVie shares in Q2 2026, an estimated $38.9K.
  • AbbVie made up 0.91% of Journey Advisory Group's portfolio in Q2 2026, its #30 holding.
  • Journey Advisory Group first reported a position in AbbVie in Q4 2020 and has held it in 23 quarters since.
  • 2,771 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Journey Advisory Group's 13F filing for Q2 2026, filed 4 Aug 2026.